Glaukos IPO

6/26/2015

IPO

$108,000,000

The principal purposes of this offering are to create a public market for our common stock, obtain additional capital, facilitate our future access to the public equity markets, increase awareness of our company among potential customers and improve our competitive position. We intend to use the net proceeds of this offering as follows: approximately $20.0 million to hire additional sales, marketing and customer service personnel and expand marketing programs both in the United States and outside the United States; approximately $15.0 million to fund clinical studies evaluating our pipeline of products under development and regulatory approvals for such products; approximately $15.0 million for the purchase of the glaucoma-related intellectual property and other assets from our affiliate DOSE Medical Corporation, or DOSE, pursuant to an asset purchase agreement dated as of July 10, 2014; and the remainder for working capital and other general corporate purposes.

Publicly-held

Medical Devices & Instruments

229 Avenida Fabricante
San Clemente, CA 92672
USA

Transforming Open-Angle Glaucoma Management Founded in 2001 and headquartered in Orange County, California, Glaukos Corporation is an ophthalmic medical device company that is committed to transforming the management of open-angle glaucoma.